论文部分内容阅读
目的:初步探讨α-2b普通干扰素治疗不同基因型HBeAg阳性慢性乙型肝炎临床疗效。方法:选择HBeAg阳性慢性乙型肝炎患者71例,采用荧光定量PCR法测定HBV基因型,并作治疗前临床资料及治疗后疗效进行统计学分析。结果:71例病例中,基因B型20例(28%),C型51例(72%),B、C基因型在ALT、HBV DNA上无统计学意义(P>0.05),α-2b普通干扰素治疗中,B、C基因组完全应答率有统计学差异(P<0.05)。结论:α-干扰素治疗HBeAg慢性乙型肝炎,B基因型效果优于C基因型患者,乙肝病毒基因型是预测干扰素治疗疗效的重要因素。
Objective: To investigate the clinical efficacy of α-2b common interferon in the treatment of HBeAg-positive chronic hepatitis B patients with different genotypes. Methods: Seventy-one patients with HBeAg-positive chronic hepatitis B were selected. Fluorescence quantitative PCR was used to determine the HBV genotype. The clinical data and therapeutic effect were statistically analyzed. Results: Among the 71 cases, there were 20 cases (28%) in genotype B and 51 cases (72%) in genotype C, but there was no significant difference in ALT and HBV DNA between genotypes B and C (P> 0.05) In general interferon therapy, the complete response rate of B and C genomes was statistically significant (P <0.05). CONCLUSION: IFN-α is better than genotype C in HBeAg-B patients. Hepatitis B virus genotype is an important factor in predicting the efficacy of interferon treatment.